FXR: a target for cholestatic syndromes?
- 17 May 2006
- journal article
- review article
- Published by Informa Healthcare in Emerging Therapeutic Targets
- Vol. 10 (3) , 409-421
- https://doi.org/10.1517/14728222.10.3.409
Abstract
The nuclear farnesoid X receptor (FXR) plays a pivotal role in maintaining bile acid homeostasis by regulating key genes involved in bile acid synthesis, metabolism and transport, including CYP7A1, UGT2B4, BSEP, MDR3, MRP2, ASBT, I-BABP, NTCP and OSTalpha-OSTbeta in humans. Altered expression or malfunction of these genes has been described in patients with cholestatic liver diseases. This review examines the rationale for the use of FXR ligand therapy in various cholestatic liver disorders and includes potential concerns.Keywords
This publication has 99 references indexed in Scilit:
- LXRS AND FXR: The Yin and Yang of Cholesterol and Fat MetabolismAnnual Review of Physiology, 2006
- Farnesoid X Receptor: From Structure to Potential Clinical ApplicationsJournal of Medicinal Chemistry, 2005
- The Farnesoid X Receptor Controls Gene Expression in a Ligand- and Promoter-selective FashionPublished by Elsevier ,2004
- Enterohepatic bile salt transporters in normal physiology and liver diseaseGastroenterology, 2004
- Natural Structural Variants of the Nuclear Receptor Farnesoid X Receptor Affect Transcriptional ActivationJournal of Biological Chemistry, 2003
- Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promotersGene, 2002
- Identification of a Nuclear Receptor for Bile AcidsScience, 1999
- Bile Acids: Natural Ligands for an Orphan Nuclear ReceptorScience, 1999
- Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BARPublished by Elsevier ,1999
- Identification of a nuclear receptor that is activated by farnesol metabolitesCell, 1995